Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
RECRUITING

Trial end date:
2028-11-01

Target enrollment:

Participant gender:

This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.

EARLY_PHASE1

Shanghai Changzheng Hospital

teprotumumab
tislelizumab